• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEF 14A filed by BioMarin Pharmaceutical Inc.

    4/8/25 4:09:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email

    Unavailable

    Get the next $BMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    5/17/2024$104.00 → $72.00Outperform → Neutral
    Robert W. Baird
    5/14/2024$113.00Outperform
    Evercore ISI
    11/15/2023$100.00Overweight
    Wells Fargo
    More analyst ratings

    $BMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioMarin Pharmaceutical upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BioMarin Pharmaceutical from Perform to Outperform and set a new price target of $98.00

      2/24/25 8:15:22 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on BioMarin Pharmaceutical with a new price target

      Wolfe Research initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $95.00

      11/15/24 7:39:24 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical downgraded by William Blair

      William Blair downgraded BioMarin Pharmaceutical from Outperform to Mkt Perform

      10/30/24 6:37:15 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

      Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025. The Phase 3 GENEr8-1

      6/24/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Hubbard Cristin covered exercise/tax liability with 2,155 shares, decreasing direct ownership by 7% to 30,545 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:02:57 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walbert Timothy P was granted 6,650 shares, increasing direct ownership by 212% to 9,780 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:01:26 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Meier Richard A was granted 6,650 shares, increasing direct ownership by 6% to 127,426 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:00:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    SEC Filings

    See more
    • SEC Form 8-K filed by BioMarin Pharmaceutical Inc.

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/22/25 4:05:34 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by BioMarin Pharmaceutical Inc.

      SC TO-C - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      5/16/25 7:59:36 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/16/25 7:54:33 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

      For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

      6/29/23 6:02:12 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care